Literature DB >> 16627417

Use of a new cardiac pacing mode designed to eliminate unnecessary ventricular pacing.

Gerd Fröhlig1, Daniel Gras, Jacques Victor, Philippe Mabo, Daniel Galley, Arnaud Savouré, Gaël Jauvert, Pascal Defaye, Pascale Ducloux, Amel Amblard.   

Abstract

AIMS: To examine the performance of AAIsafeR2, a new pacing mode to minimize the cumulative proportion of ventricular pacing in patients who do not need regular ventricular support. METHODS AND
RESULTS: The safety of AAIsafeR2 was examined in 123 recipients (73 +/- 12 years old, 51% men) of dual chamber pacemakers implanted for sinus node dysfunction, paroxysmal AV block or the bradycardia-tachycardia syndrome. Data were collected from pacemaker diagnostics, and the first 43 patients underwent 24-h Holter recordings before being discharged from the hospital with AAIsafeR2 activated. No adverse event related to AAIsafeR2 was observed. All ventricular pauses detected on Holter tapes triggered immediate back-up ventricular pacing. Appropriate switches to DDD occurred in 97 of 123 patients. In 69 of 123 devices (56%) switches to DDD were non-sustained, and the average % ventricular pacing in this group was 0.2+/-0.5%.
CONCLUSION: AAIsafeR2 mode seems to be safe and reliable in patients with infrequent slowing or pauses in ventricular activity, while maintaining ventricular pacing below 1%.

Entities:  

Mesh:

Year:  2006        PMID: 16627417     DOI: 10.1093/europace/euj024

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  8 in total

Review 1.  New concepts in physiologic cardiac pacing.

Authors:  Dwight W Reynolds; Christina M Murray
Journal:  Curr Cardiol Rep       Date:  2007-09       Impact factor: 2.931

2.  [Pacemaker ECG Quiz No. 20. Multiple ventricular extrasystoles with a little extra].

Authors:  C W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-09

3.  Non-physiological increase of AV conduction time in sinus disease patients programmed in AAIR-based pacing mode.

Authors:  Philippe Mabo; Jean-Pierre Cebron; Aude Solnon; Aude Tassin; Laurence Graindorge; Daniel Gras
Journal:  J Interv Card Electrophysiol       Date:  2012-07-27       Impact factor: 1.900

Review 4.  Clinical outcomes with biventricular versus right ventricular pacing in patients with atrioventricular conduction defects.

Authors:  Dasheng Lu; Hongxiang Zhang; Chu Chen; Kai Wang; Qijun Shan
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

5.  Very Low Ventricular Pacing Rates Can Be Achieved Safely in a Heterogeneous Pacemaker Population and Provide Clinical Benefits: The CANadian Multi-Centre Randomised Study-Spontaneous AtrioVEntricular Conduction pReservation (CAN-SAVE R) Trial.

Authors:  Bernard Thibault; Anique Ducharme; Adrian Baranchuk; Marc Dubuc; Katia Dyrda; Peter G Guerra; Laurent Macle; Blandine Mondésert; Léna Rivard; Denis Roy; Mario Talajic; Jason Andrade; Rémi Nitzsché; Paul Khairy
Journal:  J Am Heart Assoc       Date:  2015-07-23       Impact factor: 5.501

6.  Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.

Authors:  Martin Stockburger; Serge Boveda; Javier Moreno; Antoine Da Costa; Robert Hatala; Johannes Brachmann; Christian Butter; Javier Garcia Seara; Mara Rolando; Pascal Defaye
Journal:  Eur Heart J       Date:  2014-09-01       Impact factor: 29.983

7.  Effectiveness of Ventricular Intrinsic Preference (VIP™) and Ventricular AutoCapture (VAC) algorithms in pacemaker patients: Results of the validate study.

Authors:  Rakesh Yadav; Aparna Jaswal; Sridevi Chennapragada; Prakash Kamath; Shirish M S Hiremath; Dhiman Kahali; Sumit Anand; Naresh K Sood; Anil Mishra; Jitendra S Makkar; Upendra Kaul
Journal:  J Arrhythm       Date:  2015-10-01

8.  Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity-a sub-study of the ANSWER trial.

Authors:  Martin Stockburger; Pascal Defaye; Serge Boveda; Branislav Stancak; Arnaud Lazarus; Johann Sipötz; Stefano Nardi; Mara Rolando; Javier Moreno
Journal:  Europace       Date:  2015-11-26       Impact factor: 5.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.